速百纳斯制药
SUPN
37.88
-1.69
-4.27%
速百纳斯制药
US · SUPN
#2636 按市值排名
上市于 1970
37.88
-1.69
-4.27%
实时 - 追踪5344个代码 - 心跳于9秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了1家。
- 机构持股总比例下降了0.1个百分点。
机构持股
- 机构持股比例
- 104.58% -0.14pp
- 机构数量
- 398 -1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund73.59%
Hedge Fund24.03%
Individual/Insider4.33%
Public Company2.50%
VC/PE Fund1.78%
Government Pension Fund1.18%
Private Company0.73%
Insurance Company0.72%
主要股东 截至 2026-06-30
BlackRock
16.09% · 9.35M 股
Millennium Management LLC
6.63% · 3.85M 股
Vanguard Portfolio Management, LLC
5.69% · 3.31M 股
Vanguard Capital Management, LLC
4.99% · 2.90M 股
Armistice Capital LLC
4.55% · 2.65M 股
State Street Global Advisors
4.23% · 2.46M 股
Macquarie Investment Management Business Trust
4.09% · 2.38M 股
Jack Khattar
3.81% · 2.22M 股
Dimensional Fund Advisors
3.58% · 2.08M 股
Geode Capital Management, LLC
2.70% · 1.57M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 20次买入 · 26次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Jack Khattar | Founder, President, CEO, Secretary & Director | 3.81% |
| Charles Newhall | Independent Chairperson | 0.21% |
| Frederick Hudson | Independent Director | 0.10% |
| Georges Gemayel | Independent Director | 0.05% |
| Carrolee Barlow | Independent Director | 0.05% |
| Frank Mottola | Senior Vice President of Quality, GMP Operations & Information Technology | 0.03% |
| Padmanabh Bhatt | Chief Scientific Officer & Senior VP of Intellectual Property | 0.03% |
| Jonathan Rubin | Senior VP of Research & Development and Chief Medical Officer | 0.02% |
| Timothy Dec | Senior Vice President | 0.02% |
| William Horich | Senior Vice President of Marketing & Market Access | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-08-11 | Jack Khattar | Founder, President, CEO, Secretary & Director | Derivative Exercise and Sale | -12,642 | $46.57 |
| 2026-08-11 | Jack Khattar | Founder, President, CEO, Secretary & Director | Derivative Exercise and Retained | +17,207 | -- |
| 2026-08-11 | Timothy Dec | Senior Vice President | Derivative Exercise and Sale | -604 | $46.57 |
| 2026-08-11 | Timothy Dec | Senior Vice President | Derivative Exercise and Retained | +646 | -- |
| 2026-08-11 | Padmanabh Bhatt | Chief Scientific Officer & Senior VP of Intellectual Property | Derivative Exercise and Sale | -1,158 | $46.57 |
| 2026-08-11 | Padmanabh Bhatt | Chief Scientific Officer & Senior VP of Intellectual Property | Derivative Exercise and Retained | +1,342 | -- |
| 2026-08-11 | Jonathan Rubin | Senior VP of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -363 | $46.57 |
| 2026-08-11 | Jonathan Rubin | Senior VP of Research & Development and Chief Medical Officer | Derivative Exercise and Retained | +387 | -- |
| 2026-08-11 | Frank Mottola | Senior Vice President of Quality, GMP Operations & Information Technology | Derivative Exercise and Sale | -797 | $46.57 |
| 2026-08-11 | Frank Mottola | Senior Vice President of Quality, GMP Operations & Information Technology | Derivative Exercise and Retained | +853 | -- |
| 2026-07-28 | Jack Khattar | Founder, President, CEO, Secretary & Director | Other Derivative Acquisition | +29,849 | -- |
| 2026-07-28 | Timothy Dec | Senior Vice President | Other Derivative Acquisition | +1,250 | -- |
| 2026-07-28 | Padmanabh Bhatt | Chief Scientific Officer & Senior VP of Intellectual Property | Other Derivative Acquisition | +2,500 | -- |
| 2026-07-28 | Jonathan Rubin | Senior VP of Research & Development and Chief Medical Officer | Other Derivative Acquisition | +750 | -- |
| 2026-07-28 | Frank Mottola | Senior Vice President of Quality, GMP Operations & Information Technology | Other Derivative Acquisition | +1,650 | -- |
| 2026-03-17 | Padmanabh Bhatt | Chief Scientific Officer & Senior VP of Intellectual Property | Derivative Exercise and Sale | -107,250 | $27.94–50.73 |
| 2026-03-16 | Padmanabh Bhatt | Chief Scientific Officer & Senior VP of Intellectual Property | Intent to Sell (Form 144) | -57,250 | $50.21 |
| 2026-03-15 | Padmanabh Bhatt | Chief Scientific Officer & Senior VP of Intellectual Property | Intent to Sell (Form 144) | -50,000 | $49.91 |
| 2026-03-12 | Jack Khattar | Founder, President, CEO, Secretary & Director | Other Acquisition | +12,500 | -- |
| 2026-03-12 | Jack Khattar | Founder, President, CEO, Secretary & Director | Other Disposition | -12,500 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
速百纳斯制药 讨论区 0 条评论